Clinics and Practice (Jan 2024)

The Interplay between <i>Mycobacterium tuberculosis</i> and Human Microbiome

  • Michelle Nguyen,
  • Phillip Ahn,
  • John Dawi,
  • Areg Gargaloyan,
  • Anthony Kiriaki,
  • Tiffany Shou,
  • Kevin Wu,
  • Kian Yazdan,
  • Vishwanath Venketaraman

DOI
https://doi.org/10.3390/clinpract14010017
Journal volume & issue
Vol. 14, no. 1
pp. 198 – 213

Abstract

Read online

Tuberculosis (TB), a respiratory disease caused by Mycobacterium tuberculosis (Mtb), is a significant cause of mortality worldwide. The lung, a breeding ground for Mtb, was once thought to be a sterile environment, but has now been found to host its own profile of microbes. These microbes are critical in the development of the host immune system and can produce metabolites that aid in host defense against various pathogens. Mtb infection as well as antibiotics can shift the microbial profile, causing dysbiosis and dampening the host immune response. Additionally, increasing cases of drug resistant TB have impacted the success rates of the traditional therapies of isoniazid, rifampin, pyrazinamide, and ethambutol. Recent years have produced tremendous research into the human microbiome and its role in contributing to or attenuating disease processes. Potential treatments aimed at altering the gut-lung bacterial axis may offer promising results against drug resistant TB and help mitigate the effects of TB.

Keywords